anti-CD7 UCART

Anti-CD7 UCART is an allogeneic chimeric antigen receptor (CAR) T-cell therapy engineered to target CD7, a transmembrane glycoprotein highly expressed on the surface of malignant T cells and some acute myeloid leukemia (AML) cells. Upon administration, these genetically modified T cells specifically recognize and bind to CD7-expressing tumor cells, leading to targeted cytotoxicity and tumor cell lysis. Anti-CD7 CAR-T therapies are being developed primarily for hematologic malignancies such as relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL), other aggressive T-cell lymphomas, and AML with high CD7 expression. The approach leverages the immune system’s ability to selectively eliminate cancerous cells while sparing normal myeloid populations due to their lack of CD7 expression[1][2][4][5].

Other names

anti-CD7 CAR T-cellsanti-CD-7 CAR T-cellsanti-CD 7 CAR T-cellsallogeneic anti-CD7 CAR T cells4SCAR7U